Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life

NCT01214837 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

751

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal Disease
Meningococcal Meningitis

Interventions

BIOLOGICAL: MenACWY-CRM
BIOLOGICAL: MenACWY-CRM
BIOLOGICAL: Routine Vaccines

Sponsor

Novartis Vaccines